Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

National Glaucoma Research
Current Award

Dr. Beatrice Yue

Beatrice Yue, Ph.D.

University of Illinois Medical Center
Chicago, IL

Title: Fibril/Oligomer Formation by Optineurin In Vitro
Non-Technical Title: Can Optineurin Protein Aggregate to Form Toxic Amyloid-Like Fibrils or Oligomers?

Duration: July 1, 2013 - June 30, 2015
Award Type: Standard
Award Amount: $100,000

Summary:

Protein aggregation into multimers, or the so-called amyloid fibers, is a hallmark in neurodegenerative disorders such as Alzheimer’s disease. As glaucoma is considered to be an “ocular Alzheimer’s disease,” Dr. Yue and colleagues are interested in learning whether the optineurin protein, a product of glaucoma disease gene, is similarly capable of forming aggregates and causing problems, especially in situations where optineurin is found to be mutated. If so, Dr. Yue will find a way to minimize or prevent the aggregation for developing future therapies in the clinic.

Details:

Using modern biophysical and biochemical methods, Dr. Yue intends to find ways to minimize, prevent, or avert (rescue) the optineurin aggregation and toxicity.

When the study is complete, the field of glaucoma will be able to answer, for the first time, the following question: Can optineurin aggregate to form toxic amyloid fibrils or oligomers? The rescue experiments will provide important information for the development of therapies to prevent optineurin-related glaucoma.

Investigator Biography:

Dr. Yue is the Thanis A. Field Professor of Ophthalmology and directs the Ocular Cell Biology Laboratory at the University of Illinois at Chicago, College of Medicine. She completed her doctoral studies at Washington University, St. Louis. Dr. Yue’s laboratory has worked on the biology of the trabecular meshwork in health and diseases. They are currently focusing on studies of glaucoma genes optineurin and myocilin. Her research program has been continually funded by the National Eye Institute for more than 25 years.